Ardelyx Grants Stock Options & RSUs to New Employees
Ardelyx wins FDA approval for phosphate absorption inhibitor - Pharmaceutical Technology
SEC Filing | Ardelyx, Inc.
Hyperphosphatemia Pipeline Insight Report 2023 (Updated)
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities | Ardelyx, Inc.
ARDX / Ardelyx, Inc. - Put/Call Ratio, Options Sentiment, Unusual Options Activity
Positive FDA AdCom votes for Ardelyx's tenapanor
Ardelyx
Ardelyx, Inc. (ARDX) Stock Price, Quote & News - Stock Analysis
Ardelyx (@ardelyx) / X
SEC Filing | Ardelyx, Inc.
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript
Scripts : r/ARDELYX
Ardelyx on X: "Press Release: FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor) Read more here: https://t.co/drMd3jYvKl https://t.co/DYmGNsa9Nt" / X
AFTER HOUR TRADING IS HALTED : r/ARDELYX
Ardelyx Inc Stock News | ARDX Company Stock News and Press Releases | FinancialContent Business Page
Ardelyx Announces Proposed Public Offering of Common Stock
Ardelyx
FY2023 Earnings Forecast for Ardelyx, Inc. (NASDAQ:ARDX) Issued By Cantor Fitzgerald - MarketBeat
Ardelyx, Inc. (NASDAQ: ARDX) Long Term Investor Notice: Lawsuit
Adding Ardelyx (ARDX) $1.57 to Watch List. | Internet | Biotech Stock Review
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial | PDF | Chronic Kidney Disease | Therapy
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
Ardelyx Inc.(NASDAQ: ARDX)-Can it Continue to Outdo Estimates?
